• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Keywords » naltrexone

Items Tagged with 'naltrexone'

ARTICLES

polydipsia.jpeg

Management of Psychogenic Polydipsia

July 11, 2022
Victoria Hendrick, MD and Zachary Davis

Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.


Read More

Management of Psychogenic Polydipsia

March 23, 2022
Susie Morris, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Susie Morris, MD. Assistant professor of psychiatry and forensic psychiatrist, UCLA. Los Angeles, CA. Dr. Morris has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Compulsive water drinking, or psychogenic polydipsia, is surprisingly common on inpatient psychiatric units. We learn how to diagnose and manage this potentially life-threatening condition.
Read More

Meds for Alcohol Use Disorders

January 18, 2022
Mikveh Warshaw, NP.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Mikveh Warshaw, NP. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Naltrexone has shown efficacy for the treatment of alcohol use disorder in tightly controlled trials. Here, researchers demonstrate the efficacy of naltrexone in a large scale naturalistic study.
Read More

Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?

November 5, 2021
Gregory Lande, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Gregory Lande, MD. Dr. Lande has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Buprenorphine and long acting injectable naltrexone are both effective for the treatment of opioid use disorder; however, until now, we had little data to predict which patients would do better on which medications. Here, researchers identify patient characteristics predictive of success on buprenorphine versus naltrexone.
Read More

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

July 14, 2021
Farah Khorassani, PharmD. Clinical Assistant
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
With so many weight loss medications on the market, it’s hard to know which to choose. Dr. Khorassani tells us everything we need to know to about selecting and prescribing these agents. Also, she gives us additional tips for managing antipsychotic-induced weight gain.
Read More

The COMBINE Study: A Core Paper in the Treatment of AUD

November 22, 2019
Brian Frankel, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
This research update summarizes the results of the landmark COMBINE study which evaluated the effectiveness of stand-alone and combined pharmacological and behavioral interventions for treating alcohol use disorder.
Read More

Treating Alcohol Use Disorder

October 2, 2019
Albert J. Arias, MD, MS
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Albert J. Arias, MD, MSAlbert J. Arias, MD, MS
Associate Professor, Psychiatry Virginia Commonwealth University School of Medicine. Associate Division Chair, Addiction Psychiatry and Addiction Medicine. Dr. Arias has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
We have five main medications to offer patients with alcohol use disorder: acamprosate, disulfiram, gabapentin, naltrexone (PO or IM), and topiramate. The combination of naltrexone and gabapentin may work better than either of these two medications alone.
Read More

Treating Addiction in Patients Transitioning to/from Incarceration

August 1, 2019
Karen Cropsey, PsyD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Karen Cropsey, PsyDKaren Cropsey, PsyD

Conatser Turner Endowed Professor of Psychiatry, University of Alabama at Birmingham. 

Dr. Cropsey has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction treatment during incarceration is limited, and release from incarceration presents its own set of challenges. In this QA interview, Dr. Karen Cropsey discusses effective treatment options for patients with substance use disorders transitioning to or from incarceration.
Read More

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

May 21, 2019
Jessica Goren, PharmD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Jessica Goren, PharmD. Dr. Goren has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone?
Read More

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

May 21, 2019
Brian Frankel, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Brian Frankel, MD. Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade.
Read More
More Articles Tagged with 'naltrexone'
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto11543850.jpg
    General Psychiatry

    Elvis, Adderall, and a Broken Heart - Part 1

    A new medical investigation changes our understanding of Elvis Presley’s untimely death and offer some pearls for modern psychiatric practice.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.